BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33321450)

  • 1. A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI.
    Li L; Shiradkar R; Leo P; Algohary A; Fu P; Tirumani SH; Mahran A; Buzzy C; Obmann VC; Mansoori B; El-Fahmawi A; Shahait M; Tewari A; Magi-Galluzzi C; Lee D; Lal P; Ponsky L; Klein E; Purysko AS; Madabhushi A
    EBioMedicine; 2021 Jan; 63():103163. PubMed ID: 33321450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
    Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
    Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
    Merriman KM; Harmon SA; Belue MJ; Yilmaz EC; Blake Z; Lay NS; Phelps TE; Merino MJ; Parnes HL; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B
    AJR Am J Roentgenol; 2023 Dec; 221(6):773-787. PubMed ID: 37404084
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
    Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
    Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
    Sandeman K; Eineluoto JT; Pohjonen J; Erickson A; Kilpeläinen TP; Järvinen P; Santti H; Petas A; Matikainen M; Marjasuo S; Kenttämies A; Mirtti T; Rannikko A
    PLoS One; 2020; 15(7):e0235779. PubMed ID: 32645056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR-based prognostic nomogram for prostate cancer after radical prostatectomy.
    Zhang YD; Wu CJ; Bao ML; Li H; Wang XN; Liu XS; Shi HB
    J Magn Reson Imaging; 2017 Feb; 45(2):586-596. PubMed ID: 27654116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: Preliminary findings.
    Shiradkar R; Ghose S; Jambor I; Taimen P; Ettala O; Purysko AS; Madabhushi A
    J Magn Reson Imaging; 2018 Dec; 48(6):1626-1636. PubMed ID: 29734484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
    Glass AG; Leo MC; Haddad Z; Yousefi K; du Plessis M; Chen C; Choeurng V; Abdollah F; Robbins B; Ra S; Richert-Boe KE; Buerki C; Pearson K; Davicioni E; Weinmann S
    J Urol; 2016 Jun; 195(6):1748-53. PubMed ID: 26626216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
    Athanasiou A; Tennstedt P; Wittig A; Huber R; Straub O; Schiess R; Steuber T
    PLoS One; 2021; 16(11):e0259093. PubMed ID: 34767586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
    Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
    ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity.
    Campbell JM; Raymond E; O'Callaghan ME; Vincent AD; Beckmann KR; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti KL
    Clin Genitourin Cancer; 2017 Oct; 15(5):e827-e834. PubMed ID: 28666689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a Preoperative Radiologic-Risk Signature for Predicting the Pathologic Status of Prostate Cancer at Radical Prostatectomy.
    Qi L; Wu CJ; Zhang J; Bao ML; Yan X; Zhang YD
    AJR Am J Roentgenol; 2018 Oct; 211(4):805-811. PubMed ID: 29995494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J; Chun FK; Klein EA; Reuther A; Saad F; Graefen M; Huland H; Karakiewicz PI
    J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
    Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
    J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.